Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.

Literature DB >> 29491695

Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.

Samantha Rosenthal, Arnold G Decano, Aiman Bandali, Denise Lai, Gregory E Malat, Tiffany E Bias.

Abstract

Oritavancin (Orbactiv): a new-generation lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.

Entities: Chemical

Year: 2018 PMID： 29491695 PMCID： PMC5821239

Source DB: PubMed Journal: P T ISSN： 1052-1372

20 in total

1. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Authors: Adam Belley; Geoffrey A McKay; Francis F Arhin; Ingrid Sarmiento; Sylvain Beaulieu; Ibthihal Fadhil; Thomas R Parr; Gregory Moeck
Journal: Antimicrob Agents Chemother Date: 2010-09-27 Impact factor: 5.191

2. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.

Authors: Paul G Ambrose; George L Drusano; William A Craig
Journal: Clin Infect Dis Date: 2012-04 Impact factor: 9.079

3. Oritavancin: mechanism of action.

Authors: George G Zhanel; Frank Schweizer; James A Karlowsky
Journal: Clin Infect Dis Date: 2012-04 Impact factor: 9.079

4. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Authors: G Ralph Corey; Samantha Good; Hai Jiang; Greg Moeck; Matthew Wikler; Sinikka Green; Paul Manos; Richard Keech; Rajesh Singh; Barry Heller; Natalia Bubnova; William O'Riordan
Journal: Clin Infect Dis Date: 2014-10-06 Impact factor: 9.079

5. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.

Authors: Lala M Dunbar; Joe Milata; Ty McClure; Margaret M Wasilewski
Journal: Antimicrob Agents Chemother Date: 2011-05-02 Impact factor: 5.191

6. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

Authors: G Ralph Corey; Francis F Arhin; Matthew A Wikler; Daniel F Sahm; Barry N Kreiswirth; José R Mediavilla; Samantha Good; Claude Fiset; Hai Jiang; Greg Moeck; Heidi Kabler; Sinikka Green; William O'Riordan
Journal: Int J Antimicrob Agents Date: 2016-09-13 Impact factor: 5.283

7. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Authors: Adam Belley; Eve Neesham-Grenon; Geoffrey McKay; Francis F Arhin; Robert Harris; Terry Beveridge; Thomas R Parr; Gregory Moeck
Journal: Antimicrob Agents Chemother Date: 2008-12-22 Impact factor: 5.191

8. Single-dose oritavancin in the treatment of acute bacterial skin infections.

Authors: G Ralph Corey; Heidi Kabler; Purvi Mehra; Sandeep Gupta; J Scott Overcash; Ashwin Porwal; Philip Giordano; Christopher Lucasti; Antonio Perez; Samantha Good; Hai Jiang; Greg Moeck; William O'Riordan
Journal: N Engl J Med Date: 2014-06-05 Impact factor: 91.245

9. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

Authors: Adam Belley; Francis F Arhin; Ingrid Sarmiento; Hong Deng; Warren Rose; Greg Moeck
Journal: Antimicrob Agents Chemother Date: 2012-10-22 Impact factor: 5.191

10. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.

Authors: Ivar S Jensen; Elizabeth Wu; Weihong Fan; Thomas P Lodise; David P Nicolau; Scott Dufour; Philip L Cyr; Katherine A Sulham
Journal: J Manag Care Spec Pharm Date: 2016-06

3 in total